New Zealand markets closed

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.1900+0.1900 (+6.33%)
At close: 04:00PM EDT
3.1900 0.00 (0.00%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 329.26M
Enterprise value 158.89M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.33
Price/book (mrq)4.07
Enterprise value/revenue 1.13
Enterprise value/EBITDA -2.05

Trading information

Stock price history

Beta (5Y monthly) 3.41
52-week change 3-84.20%
S&P500 52-week change 3-1.04%
52-week high 325.0550
52-week low 32.9050
50-day moving average 35.3804
200-day moving average 37.0116

Share statistics

Avg vol (3-month) 3772.11k
Avg vol (10-day) 3859.71k
Shares outstanding 592.23M
Implied shares outstanding 6N/A
Float 869.55M
% held by insiders 19.01%
% held by institutions 183.85%
Shares short (12 May 2022) 45.01M
Short ratio (12 May 2022) 46.25
Short % of float (12 May 2022) 48.93%
Short % of shares outstanding (12 May 2022) 45.43%
Shares short (prior month 13 Apr 2022) 44.61M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022

Profitability

Profit margin -61.65%
Operating margin (ttm)-60.35%

Management effectiveness

Return on assets (ttm)-16.97%
Return on equity (ttm)-77.22%

Income statement

Revenue (ttm)140.7M
Revenue per share (ttm)1.53
Quarterly revenue growth (yoy)-73.90%
Gross profit (ttm)3.04M
EBITDA -78.88M
Net income avi to common (ttm)-86.74M
Diluted EPS (ttm)-0.9440
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)248M
Total cash per share (mrq)2.69
Total debt (mrq)77.63M
Total debt/equity (mrq)95.89
Current ratio (mrq)3.20
Book value per share (mrq)0.88

Cash flow statement

Operating cash flow (ttm)-30.26M
Levered free cash flow (ttm)-7.81M